|Table of Contents|

Clinical value of Hypofractionated conformal radiotherapy in combination with chemotherapy for limited disease small-cell lung cancer：A Meta analysis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 04
Page:
598-603
Research Field:
Publishing date:

Info

Title:
Clinical value of Hypofractionated conformal radiotherapy in combination with chemotherapy for limited disease small-cell lung cancer：A Meta analysis
Author(s):
Yang Haixia; Shao Qiuju; Qi Yuhong; Wang Qiming; Liang Jun
Tangdu Hospital,Fourth Military Medical University,Shaanxi Xi'an 710038，China.
Keywords:
limited disease small-cell lung cancer(LD-SCLC); Hypofractionated thoracic radiotherapy(HypoTRT); hyper- or conventionally fractionated thoracic radiotherapy(Hyper/Conv TRT); Meta analysis
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2019.04.014
Abstract:
Objective:To investigate the clinical effect of Hypofractionated thoracic radiotherapy (HypoTRT) with concurrent chemotherapy for limited disease small-cell lung cancer(LD-SCLC) through a Meta analysis．Methods:CBM,CNKI,Cochrane Library,PubMed,Medline,Web of science and Embase were searched for the articles on comparison between HypoTRT with concurrent chemotherapy and Hyper- or conventionally fractionated thoracic radiotherapy(Hyper/Conv TRT) with concurrent chemotherapy in patients with LD-SCLC.According to the inclusion and exclusion criteria,the data on short-term outcome and survival were collected.A Meta analysis was performed to evaluate the clinical effect of HypoTRT in combination with chemotherapy for LD-SCLC.Results:A total of 5 articles were included,which involved 837 patients．The results showed that the progression-free survival were similar between patients receiving HypoTRT with concurrent chemotherapy and those receiving Hyper- or conventionally fractionated radiotherapy(P=0.95),but the patients receiving Hypofractionated concurrent radiochemotherapy showed a significantly longer overall survival than those receiving Hyper/Conv TRT(P=0.03)．No significant differences in acute esophagitis and pneumonitis were demonstrated between the TRT cohorts（RR=0.86，95%CI：0.58~1.27，P=0.45；RR=0.77，95%CI：0.39~1.51，P=0.44）.Conclusion:HypoTRT with concurrent chemotherapy shows significant advantages over Hyper/Conv TRT in overall survival without extra acute toxicities,suggesting that HypoTRT can be alternative for LD-SCLC patients.

References:

［1］Siegel RL,Miller KD,Jemal A.Cancer statistics,2018［J］.CA Cancer J Clin,2018,68(1):7-30.
［2］Palma DA,Warner A,Louie AV,et al.Thoracic radiotherapy for extensive stage small-cell lung cancer:A Meta-analysis［J］.Clin Lung Cancer,2016,17(4):239-244.
［3］Waqar SN,Morgensztern D.Treatment advances in small cell lung cancer (SCLC)［J］.Pharmacol Ther,2017,180:16-23.
［4］Lu H,Jiang Z.Advances in antibody therapeutics targeting small-cell lung cancer［J］.Adv Clin Exp Med,2018,27(9):1-8.
［5］Pignon JP,Arriagada R,Ihde DC,et al.A meta-analysis of thoracic radiotherapy for small-cell lung cancer［J］.N Engl J Med,1992,327(23):1618-1624.
［6］Warde P,Payne D.Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis［J］.J Clin Oncol,1992,10(6):890-895.
［7］De Ruysscher D,Lueza B,Le Pechoux C,et al.Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer:Usefulness of the individual patient data meta-analysis［J］.Ann Oncol,2016,27(10):1818-1828.
［8］De Ruysscher D.Treatment of limited disease small cell lung cancer［J］.Front Radiat Ther Oncol,2010,42(1):173-179.
［9］Nakahara Y,Sasaki J,Fukui T,et al.The role of prophylactic cranial irradiation for patients with small-cell lung cancer［J］.Jpn J Clin Oncol,2018,48(1):26-30.
［10］Rodriguez de Dios N,Calvo P,Rico M,et al.Recent developments in radiotherapy for small-cell lung cancer:a review by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)［J］.Clin Transl Oncol,2017,19(10):1183-1192.
［11］Shao WP,Wang XW,Liu DR.Recent advances and future strategies for small cell lung cancer［J］.Chinese Journal of Lung Canceri,2017,20(6):421-426.［邵为朋，王晓伟，刘德若.小细胞肺癌目前治疗的策略与未来方向［J］.中国肺癌杂志，2017,20(6):421-426.］
［12］You J,Yu HM,Song MXW,et al.Phase I study of etoposide and cisplatin chemotherapy dose escalation with concurrent twice-daily radiotherapy for patients with limited-stage small cell lung cancer［J］.Chinese Journal of Lung Canceri,2017,20(1):55-60.［尤静，于会明，宋马小薇，等.局限期小细胞肺癌加速超分割放疗同步EP方案化疗的剂量递增Ⅰ期研究［J］.中国肺癌杂志，2017,20(1):55-60.］
［13］Gensheimer MF,Loo BW.Optimal radiation therapy for small cell lung cancer［J］.Curr Treat Options Oncol,2017,18(21):1-9.
［14］Kalemkerian GP.Small cell lung cancer［J］.Semin Respir Crit Care Med,2016,37(5):783-796.
［15］Turrisi AT,Kim K,Blum R,et al.Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide［J］.N Engl J Med,1999,340(4):265-271.
［16］Faivre-Finn C,Snee M,Ashcroft L,et al.Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT):An open-label,phase 3,randomised,superiority trial［J］.The Lancet Oncology,2017,18(8):1116-1125.
［17］Grant JD,Shirvani SM,Tang C,et al.Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer［J］.Pract Radiat Oncol,2015,5(4):e383-391.
［18］Falkson CB,vella ET,Yu E,et al.Radiotherapy with curative intent in patients with early-stage,medically inoperable,non-small-cell lung cancer:A systematic review［J］.Clin Lung Cancer,2017,18(2):105-121.
［19］McGarry RC.Integrating stereotactic body radiation therapy in stage II/III non-small cell lung cancer:is local control important［J］?Expert Rev Anticancer Ther,2014,14(12):1419-1427.
［20］Bettington CS,Tripcony L,Bryant G,et al.A retrospective analysis of survival outcomes for two different radiotherapy fractionation schedules given in the same overall time for limited stage small cell lung cancer［J］.J Med Imaging Radiat Oncol,2013,57(1):105-112.
［21］Zhang J,Fan M,Liu D,et al.Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer［J］.Radiat Oncol,2017,12 (51):1-7.
［22］Socha J,Guzowska A,Tyc-Szczepaniak D,et al.Hypofractionated conformal radiotherapy in combination with chemotherapy in limited disease small cell lung cancer patients［J］.Pneumonol Alergol Pol,2014,82(2):105-115.
［23］Grnberg BH,Halvorsen TO,Flotten O,et al.Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer［J］.Acta Oncol,2016,55(5):591-597.
［24］Videtic GM,Truong PT,Dar AR,et al.Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy:A single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation［J］.International Journal of Radiation Oncology Biology Physics,2003,57(3):709-716.
［25］Parmar MK,Torri V,Stewart L.Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints［J］.Stat Med,1998,17(24):2815-2834.
［26］De Ruysscher D,Pijls-Johannesma M,Bentzen SM,et al.Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer［J］.J Clin Oncol,2006,24(7):1057-1063.
［27］Lee KJ,Lee EJ,Hur GY,et al.The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer［J］.Korean J Intern Med,2013,28(4):449-455.
［28］Brade AM,Tannock IF.Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer:repopulation as a cause of treatment failure［J］?J Clin Oncol,2006,24(7):1020-1022.
［29］Arriagada R,Le Chevalier T,Ruffie P,et al.Alternating radiotherapy and chemotherapy in limited small cell lung cancer:the IGR protocols.French FNCLCC Lung Cancer Study Group［J］.Lung Cancer,1994,10(Suppl 1):S289-298.
［30］Ye Xiupeng,Ma Xiaoping,Bao Shen,et al.Hypo fractionated radiation therapy for breast cancer:A Meta analysis［J］.Modern Oncology,2015,23(16):2292-2300.［冶秀鹏,马小萍,包慎,等.早期乳腺癌保乳术后大分割放疗的Meta分析［J］.现代肿瘤医学，2015,23(16):2292-2300.］

Memo

Memo:
-
Last Update: 1900-01-01